Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab.

J Clin Med · 2026 · PMC13116606 · PMID 42074824

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In patients with metastatic squamous NSCLC, the IMpower131 trial showed a significant improvement in PFS with atezolizumab combined with chemotherapy, although the OS difference did not reach statistical significance [ 126 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.